Overview Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy Status: Completed Trial end date: 2008-11-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine whether QR-333 is safe and effective in the treatment of diabetic neuropathy as compared to placebo. Phase: Phase 2 Details Lead Sponsor: Quigley Pharma, Inc.